Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective

OBJECTIVE: Given the high economic burden of disease among adult patients with chronic heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event in the US, this study aimed to estimate the cost effectiveness of vericiguat plus prior standard-of-care therapies (PS...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsumali, Adnan, Djatche, Laurence M, Briggs, Andrew, Liu, Rongzhe, Diakite, Ibrahim, Patel, Dipen, Wang, Yufei, Lautsch, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516766/
https://www.ncbi.nlm.nih.gov/pubmed/34623625
http://dx.doi.org/10.1007/s40273-021-01091-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516766/
https://www.ncbi.nlm.nih.gov/pubmed/34623625
http://dx.doi.org/10.1007/s40273-021-01091-w

Ejemplares similares